Lee DE et al., 2022: Pancreatic cancer study reporting that ivermectin plus gemcitabine suppresses PANC-1 xenograft growth more than gemcitabine alone, with G1 arrest and mTOR/STAT3 inhibition curbing proliferation and mitochondrial dysfunction and ROS driving apoptosis.
When tumors reached approximately 150 mm3, mice were randomized into four groups (n = 6). Gemcitabine (10 mg/kg) and ivermectin (5 mg/kg) were intraperitoneally injected twice a week for 21 days.
n/a (HTML full text, Methods)
Lee DE et al., 2022: Pancreatic cancer study reporting that ivermectin plus gemcitabine suppresses PANC-1 xenograft growth more than gemcitabine alone, with G1 arrest and mTOR/STAT3 inhibition curbing proliferation and mitochondrial dysfunction and ROS driving apoptosis. Study type: pancreatic cancer cell lines + PANC-1 nude mouse xenograft. N: 6 mice per group, 4 groups. Country: South Korea (Yonsei University, Seoul). Dose: ivermectin 5 mg/kg and gemcitabine 10 mg/kg intraperitoneally twice weekly for 21 days; comparator: vehicle, each single agent. Declared COI: none declared. This is also the source of the pancreatic organoid data cited in the gynaecologic review (IVC-09). Also filed as IVA-31 (claims C7, C9). Study type: animal.
